Hank Lockman

2.4k total citations
32 papers, 1.8k citations indexed

About

Hank Lockman is a scholar working on Endocrinology, Immunology and Molecular Medicine. According to data from OpenAlex, Hank Lockman has authored 32 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, 9 papers in Immunology and 8 papers in Molecular Medicine. Recurrent topics in Hank Lockman's work include Vibrio bacteria research studies (10 papers), Antibiotic Resistance in Bacteria (8 papers) and Aquaculture disease management and microbiota (8 papers). Hank Lockman is often cited by papers focused on Vibrio bacteria research studies (10 papers), Antibiotic Resistance in Bacteria (8 papers) and Aquaculture disease management and microbiota (8 papers). Hank Lockman collaborates with scholars based in United States, Japan and Spain. Hank Lockman's co-authors include James B. Kaper, Rita R. Colwell, Sudha Joseph, Roy Curtiss, Myron M. Levine, Mary M. Baldini, Ramon J. Seidler, Alison D. O’Brien, Richard M. Conran and Elaine F. Remmers and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Hank Lockman

32 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hank Lockman United States 21 1.2k 709 455 451 286 32 1.8k
Mahendra H. Kothary United States 27 1.3k 1.1× 534 0.8× 548 1.2× 511 1.1× 338 1.2× 54 2.5k
P R Brayton United States 27 913 0.8× 740 1.0× 252 0.6× 658 1.5× 509 1.8× 41 2.7k
Irma Nelly Gutierrez Rivera Brazil 20 905 0.8× 526 0.7× 316 0.7× 354 0.8× 230 0.8× 36 1.5k
Soo Young Kim South Korea 19 883 0.8× 765 1.1× 242 0.5× 848 1.9× 251 0.9× 30 2.1k
Shin‐ichi Miyoshi Japan 24 1.2k 1.1× 730 1.0× 329 0.7× 664 1.5× 171 0.6× 115 1.8k
Jorge A. Benítez United States 27 1.2k 1.1× 557 0.8× 209 0.5× 777 1.7× 234 0.8× 57 1.8k
Sylvia M. Kirov Australia 23 607 0.5× 824 1.2× 168 0.4× 689 1.5× 327 1.1× 50 1.7k
Dolores Castro Spain 26 454 0.4× 1.2k 1.7× 131 0.3× 426 0.9× 312 1.1× 73 1.7k
N C Roberts United States 9 795 0.7× 366 0.5× 262 0.6× 329 0.7× 282 1.0× 11 1.3k
Shin-ichi Miyoshi Japan 21 973 0.8× 632 0.9× 327 0.7× 614 1.4× 140 0.5× 76 1.6k

Countries citing papers authored by Hank Lockman

Since Specialization
Citations

This map shows the geographic impact of Hank Lockman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hank Lockman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hank Lockman more than expected).

Fields of papers citing papers by Hank Lockman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hank Lockman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hank Lockman. The network helps show where Hank Lockman may publish in the future.

Co-authorship network of co-authors of Hank Lockman

This figure shows the co-authorship network connecting the top 25 collaborators of Hank Lockman. A scholar is included among the top collaborators of Hank Lockman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hank Lockman. Hank Lockman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stephens, Deborah M., Ying Huang, Amy S. Ruppert, et al.. (2022). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical Cancer Research. 28(15). 3242–3247. 20 indexed citations
2.
Stephens, Deborah M., Ying Huang, Akwasi Agyeman, et al.. (2019). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study. Blood. 134(Supplement_1). 4310–4310. 4 indexed citations
3.
Fellows, Patricia, et al.. (2015). Characterization of a Cynomolgus Macaque Model of Pneumonic Plague for Evaluation of Vaccine Efficacy. Clinical and Vaccine Immunology. 22(9). 1070–1078. 10 indexed citations
4.
Warren, Robin M., Hank Lockman, Roy E. Barnewall, et al.. (2010). Cynomolgus macaque model for pneumonic plague. Microbial Pathogenesis. 50(1). 12–22. 21 indexed citations
5.
Huang, Dan, Crystal Y. Chen, Zahida Ali, et al.. (2009). Antigen-specific Vγ2Vδ2 T effector cells confer homeostatic protection against pneumonic plaque lesions. Proceedings of the National Academy of Sciences. 106(18). 7553–7558. 42 indexed citations
6.
Wild, Martha A., et al.. (2008). A human antibody against anthrax protective antigen protects rabbits from lethal infection with aerosolized spores. Human Antibodies. 16(3-4). 99–105. 6 indexed citations
7.
Lockman, Hank, Rebecca A. Gillespie, Beth Baker, & Elizabeth A. Shakhnovich. (2002). Yersinia pseudotuberculosis Produces a Cytotoxic Necrotizing Factor. Infection and Immunity. 70(5). 2708–2714. 55 indexed citations
8.
9.
Andreu, Antònia, Ann E. Stapleton, C. L. Fennell, et al.. (1997). Urovirulence Determinants inEscherichia coliStrains Causing Prostatitis. The Journal of Infectious Diseases. 176(2). 464–469. 73 indexed citations
10.
Lockman, Hank & Roy Curtiss. (1992). Isolation and characterization of conditional adherent and non‐type 1 fimbriated Salmonella typhimurium mutants. Molecular Microbiology. 6(7). 933–945. 27 indexed citations
11.
Lockman, Hank & Roy Curtiss. (1990). Occurrence of Secondary Attenuating Mutations in Avirulent Salmonella typhimurium Vaccine Strains. The Journal of Infectious Diseases. 162(6). 1397–1400. 6 indexed citations
12.
Lockman, Hank & Roy Curtiss. (1990). Salmonella typhimurium mutants lacking flagella or motility remain virulent in BALB/c mice. Infection and Immunity. 58(1). 137–143. 104 indexed citations
13.
Kaper, James B., Hank Lockman, Mary M. Baldini, & Myron M. Levine. (1984). Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature. 308(5960). 655–658. 154 indexed citations
14.
Lockman, Hank, James E. Galen, & James B. Kaper. (1984). Vibrio cholerae enterotoxin genes: nucleotide sequence analysis of DNA encoding ADP-ribosyltransferase. Journal of Bacteriology. 159(3). 1086–1089. 23 indexed citations
15.
Lockman, Hank & James B. Kaper. (1983). Nucleotide sequence analysis of the A2 and B subunits of Vibrio cholerae enterotoxin.. Journal of Biological Chemistry. 258(22). 13722–13726. 84 indexed citations
16.
Levine, Myron M., James B. Kaper, Hank Lockman, et al.. (1983). Recombinant DNA Risk Assessment Studies in Humans: Efficacy of Poorly Mobilizable Plasmids in Biologic Containment. The Journal of Infectious Diseases. 148(4). 699–709. 27 indexed citations
17.
Kaper, James B., Hank Lockman, Rita R. Colwell, & Sudha Joseph. (1981). Aeromonas hydrophila : Ecology and Toxigenicity of Isolates from an Estuary. Journal of Applied Bacteriology. 50(2). 359–377. 186 indexed citations
18.
Kaper, James B., et al.. (1980). R-factor carriage in a group F vibrio isolated from Bangladesh. Antimicrobial Agents and Chemotherapy. 17(3). 512–515. 11 indexed citations
19.
Huq, I, James B. Kaper, Hank Lockman, et al.. (1980). Isolation of drug-resistant Aeromonas hydrophila from aquatic environments. Antimicrobial Agents and Chemotherapy. 17(3). 477–483. 40 indexed citations
20.
Kaper, James B., Ramon J. Seidler, Hank Lockman, & R. R. Colwell. (1979). Medium for the presumptive identification of Aeromonas hydrophila and Enterobacteriaceae. Applied and Environmental Microbiology. 38(5). 1023–1026. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026